Description
Biocon Ltd. has listed 112,664,585 equity shares on BSE pursuant to Qualified Institutional Placement, effective January 20, 2026.
Summary
Biocon Ltd. (Scrip Code: 532523, ISIN: INE376G01013) has listed 112,664,585 new equity shares of Rs. 5 each on BSE, allotted to Qualified Institutional Buyers (QIBs) through a Qualified Institutional Placement. The shares will be available for trading from January 20, 2026, and rank pari-passu with existing equity shares.
Key Points
- 112,664,585 equity shares of Rs. 5 each listed
- Allotted to QIBs pursuant to Qualified Institutional Placement
- Issue price: Rs. 368.35 per share
- Date of allotment: January 14, 2026
- Distinctive numbers: 1508243189 to 1620907773
- New shares rank pari-passu with existing equity shares
- Scrip Code: 532523
- ISIN: INE376G01013
Regulatory Changes
No regulatory changes. This is a routine listing notification for new securities issued through QIP.
Compliance Requirements
Trading members should note the listing of new securities and update their systems accordingly. The new shares are available for trading with effect from January 20, 2026.
Important Dates
- January 14, 2026: Date of allotment
- January 19, 2026: Notice date
- January 20, 2026: Effective date for trading of new securities
Impact Assessment
The QIP has resulted in significant capital raise for Biocon Ltd., with over 112 million shares issued at Rs. 368.35 per share, translating to approximately Rs. 4,150 crores. This represents a material dilution for existing shareholders but provides substantial capital to the company. The shares being pari-passu ensures equal rights with existing equity holders. Market impact is expected to be moderate as QIPs to institutional investors are typically well-absorbed.
Impact Justification
Large QIP listing by major pharmaceutical company; significant dilution but routine corporate action for existing listed entity